Fig. 5: NIC dependent increased EZH2 expression is a result of upregulated Myc in response to NIC.

a, b Graph depicts correlation between EZH2 and Myc in breast cancer cell lines and primary breast tumor respectively. c (i), d (i) Immunoblot shows NIC-mediated altered expression of α9-nAChR, Myc, and EZH2 in breast cancer cells and xenograft respectively. c (ii) and d (ii) Densitometry analysis of the respective immunoblot is displayed in the graph. e (i) and (ii) Effect of Bupropion (1 µM) treatment on NIC-mediated response is displayed by the western blot and densitometry graph, respectively. f Fold enrichment of Myc on EZH2 promoter in control and NIC-treated MDA-MB-231 cells is depicted in the graph as observed by CHIP-qPCR assay. g Corresponding agarose gel picture of the CHIP-qPCR product showing the expression of the EZH2 (E-box element containing) promoter region amplified with immunoprecipitated-Myc as a template in both control and NIC-treated cells. h Diagram depicts the proposed pathway involved in EZH2-mediated increased breast cancer progression in response to NIC. Graphs are plotted with SD, which is calculated from three independent experiments. Two-tailed paired Student t-test was used for statistical analysis. *P < 0.05